Clinical Trial

Safety and Efficacy of Subretinal Transplantation of Clinical Human Embryonic Stem Cell Derived Retinal Pigment Epitheliums in Treatment of Retinitis Pigmentosa

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This project intends to transplant a clinical level human embryonic stem cells derived retinal pigment epithelium into subretinal space to treat eetinitis pigmentosa(RP) diseases. Through the statistical analysis EDTRS, BCVA, OCT, ERG, Fluorescein angiography, Ophthalmic AB ultrasound changes between before and after the treatment to assess the efficacy and safety 0f RPE transplants to treat RP disease.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2019-05-08; most recent amendment 2026-07-02.
Status change: Recruiting → Active, Not Recruiting 2026-07-02
Trial Details
NCT Number NCT03944239
Lead Sponsor Qi Zhou
Collaborators: Beijing Tongren Hospital
Conditions Retinitis Pigmentosa
Enrollment 25 participants
Start Date 2021-05-19
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-06